skip to main content
Language:
Show Results with:

Results 1 - 10 of 14  for Everything in this catalogue

Sort by: Sort by: relevanceOr hit Enter to replace sort method
results 1 2 next page
Refined by: author: Palmer, A. J. remove access option: Online: Reading Room only remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting
Material Type:
Article 		Add to My workspace

Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting

Roze, S. et al.

Current medical research and opinion. VOL 22; NUMB 7, ; 2006, 1415-1424 -- LIBRA PHARM LTD (pages 1415-1424) -- 2006

Online access

2
What Impact Would Pancreatic Beta-cell Preservation Have on Life Expectancy, Quality-adjusted Life Expectancy and Costs of Complications in Patients with Type 2 Diabetes? A Projection Using the CORE Diabetes Model
What Impact Would Pancreatic Beta-cell Preservation Have on Life Expectancy, Quality-adjusted Life Expectancy and Costs of Complications in Patients with Type 2 Diabetes? A Projection Using the CORE Diabetes Model
Material Type:
Article 		Add to My workspace

What Impact Would Pancreatic Beta-cell Preservation Have on Life Expectancy, Quality-adjusted Life Expectancy and Costs of Complications in Patients with Type 2 Diabetes? A Projection Using the CORE Diabetes Model

Palmer, A. J. et al.

Current medical research and opinion. VOL 20; SUPP/1, ; 2004, S59-S66 -- LIBRA PHARM LTD (pages S59-S66) -- 2004

Online access

3
Deleterious Effects of Increased Body Weight Associated with Intensive Insulin Therapy for Type 1 Diabetes: Increased Blood Pressure and Worsened Lipid Profile Partially Negate Improvements in Life Expectancy
Deleterious Effects of Increased Body Weight Associated with Intensive Insulin Therapy for Type 1 Diabetes: Increased Blood Pressure and Worsened Lipid Profile Partially Negate Improvements in Life Expectancy
Material Type:
Article 		Add to My workspace

Deleterious Effects of Increased Body Weight Associated with Intensive Insulin Therapy for Type 1 Diabetes: Increased Blood Pressure and Worsened Lipid Profile Partially Negate Improvements in Life Expectancy

Palmer, A. J. et al.

Current medical research and opinion. VOL 20; SUPP/1, ; 2004, S67-S73 -- LIBRA PHARM LTD (pages S67-S73) -- 2004

Online access

4
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension
Material Type:
Article 		Add to My workspace

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension

Palmer, A. J. et al.

Current medical research and opinion. VOL 22; NUMB 11, ; 2006, 2095-2100 -- LIBRA PHARM LTD (pages 2095-2100) -- 2006

Online access

5
Counting the costs of overweight and obesity: modeling clinical and cost outcomes
Counting the costs of overweight and obesity: modeling clinical and cost outcomes
Material Type:
Article 		Add to My workspace

Counting the costs of overweight and obesity: modeling clinical and cost outcomes

Tucker, D. M. D. et al.

Current medical research and opinion. VOL 22; NUMB 3, ; 2006, 575-586 -- LIBRA PHARM LTD (pages 575-586) -- 2006

Online access

6
Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes
Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes
Material Type:
Article 		Add to My workspace

Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes

Palmer, A. J. et al.

Current medical research and opinion. VOL 22; NUMB 5, ; 2006, 861-872 -- LIBRA PHARM LTD (pages 861-872) -- 2006

Online access

7
Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials
Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials
Material Type:
Article 		Add to My workspace

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials

Palmer, A. J. et al.

Current medical research and opinion. VOL 20; NUMB 11, ; 2004, 1729-1746 -- LIBRA PHARM LTD (pages 1729-1746) -- 2004

Online access

8
Impact of Changes in HbA~1~0, Lipids and Blood Pressure on Long-term Outcomes in Type 2 Diabetes Patients: An Analysis Using the CORE Diabetes Model
Impact of Changes in HbA~1~0, Lipids and Blood Pressure on Long-term Outcomes in Type 2 Diabetes Patients: An Analysis Using the CORE Diabetes Model
Material Type:
Article 		Add to My workspace

Impact of Changes in HbA~1~0, Lipids and Blood Pressure on Long-term Outcomes in Type 2 Diabetes Patients: An Analysis Using the CORE Diabetes Model

Palmer, A. J. et al.

Current medical research and opinion. VOL 20; SUPP/1, ; 2004, S53-S58 -- LIBRA PHARM LTD (pages S53-S58) -- 2004

Online access

9
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain
Material Type:
Article 		Add to My workspace

Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain

Ray, J. A. et al.

Current medical research and opinion. VOL 21; NUMB 10, ; 2005, 1617-1630 -- LIBRA PHARM LTD (pages 1617-1630) -- 2005

Online access

10
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes
Material Type:
Article 		Add to My workspace

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

Ray, J. A. et al.

Current medical research and opinion. VOL 23; NUMB 3, ; 2007, 609-622 -- LIBRA PHARM LTD (pages 609-622) -- 2007

Online access

Results 1 - 10 of 14  for Everything in this catalogue

Sort by: Sort by: relevanceOr hit Enter to replace sort method
results 1 2 next page

Refine Search Results

Creation date 

From To
Refine

Try a new search

Ignore my search and look for everything

by this Author/Contributor:

  1. Palmer, A. J.
  2. Valentine, W. J.
  3. Roze, S
  4. Lammert, M.
  5. Minshall, M. E.

on this subject:

  1. Medicine
  2. Biotechnology
  3. Pharmaceutical chemistry

All text is © British Library Board and is available under a Creative Commons Attribution Licence, except where otherwise stated.

P1

Searching Remote Databases, Please Wait